CN110373457B - 一种用于溃疡性结肠炎诊断的mRNA标志物及其应用 - Google Patents
一种用于溃疡性结肠炎诊断的mRNA标志物及其应用 Download PDFInfo
- Publication number
- CN110373457B CN110373457B CN201910536229.XA CN201910536229A CN110373457B CN 110373457 B CN110373457 B CN 110373457B CN 201910536229 A CN201910536229 A CN 201910536229A CN 110373457 B CN110373457 B CN 110373457B
- Authority
- CN
- China
- Prior art keywords
- etv5
- mrna
- diagnosis
- marker
- ulcerative colitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010009900 Colitis ulcerative Diseases 0.000 title claims abstract description 52
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims abstract description 52
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 24
- 239000003550 marker Substances 0.000 title claims abstract description 19
- 238000003745 diagnosis Methods 0.000 title abstract description 15
- 102100039577 ETS translocation variant 5 Human genes 0.000 claims abstract description 40
- 101000813745 Homo sapiens ETS translocation variant 5 Proteins 0.000 claims abstract description 40
- 238000011529 RT qPCR Methods 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 238000010839 reverse transcription Methods 0.000 claims description 9
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 10
- 238000003759 clinical diagnosis Methods 0.000 abstract description 8
- 239000000101 novel biomarker Substances 0.000 abstract description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 238000000034 method Methods 0.000 description 13
- 210000005259 peripheral blood Anatomy 0.000 description 11
- 239000011886 peripheral blood Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101100012020 Homo sapiens ETV5 gene Proteins 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 3
- 238000001839 endoscopy Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010022699 Intestinal stenosis Diseases 0.000 description 1
- 206010074063 Ischaemic enteritis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 201000008267 intestinal tuberculosis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种用于溃疡性结肠炎诊断的mRNA标志物及其应用,所述标志物为SEQ ID No:1所示的ETV5。本发明提供的mRNA标志物ETV5对于诊断UC具有很高的特异性及灵敏度,可以作为新型的生物标志物用于UC的临床诊断。
Description
技术领域
本发明属于医学分子生物学技术领域,具体涉及一种用于溃疡性结肠炎诊断的mRNA标志物及其应用。
背景技术
溃疡性结肠炎(ulcerative colitis,UC)是一种主要累及结肠的慢性、非特异性的炎症性疾病,临床表现主要包括腹痛、腹泻及粘液脓血便等。虽然目前UC的发病机制仍不清楚,但是越来越多的研究表明,CD4+T细胞免疫调节功能紊乱诱导的炎症反应在UC发生发展过程中发挥关键作用。随着环境和饮食习惯改变,UC发病率在我国呈逐年上升趋势。该病易复发,常迁延不愈,有致残、癌变等风险,给患者身心造成沉重打击。
随着科技进步,UC的诊断和治疗不断发展。目前用于UC临床诊断的方法主要为内镜、组织病理学和血液检查。但是许多患者因病情严重导致肠腔狭窄、虚弱等情况,难以耐受内镜检查,使得临床诊断和病情严重程度评估受到巨大限制。血液检查包括血沉、C-反应蛋白、内毒素等指标,但是由于上述指标缺乏特异性,导致UC难以与其他消化道疾病(如:淋巴瘤、肠结核、缺血性肠炎等)相鉴别,易引起误诊,延误治疗。此外,由于发病机制尚不明确,目前UC的临床治疗亦面临巨大挑战。因此,探索UC的发病机制,寻找特异性的UC诊断标志物和治疗靶点,对我国UC的临床诊治极其重要。
人类ETS variant 5(ETV5)基因位于3号染色体上。有研究表明,ETV5在多种肿瘤性疾病及自身免疫性疾病的发生发展过程中发挥重要作用。但是ETV5基因在UC患者外周血CD4+T细胞中的表达水平及其对CD4+T细胞的免疫调节作用未见相关报道。
发明内容
针对上述现有技术的不足,本发明提供了一种用于溃疡性结肠炎诊断的mRNA标志物及其应用,该mRNA标志物为ETV5,该mRNA标志物对于诊断UC具有很高的特异性及灵敏度,可以作为新型的生物标志物用于UC的临床诊断。
为实现上述目的,本发明采用以下技术方案:
一种用于溃疡性结肠炎诊断的mRNA标志物,所述标志物为SEQ ID No:1所示的ETV5。
针对上述mRNA标志物的引物组合,包括如SEQ ID No:2所示的上游引物和如SEQID No:3所示的下游引物。
上述mRNA标志物在制备诊断溃疡性结肠炎的产品中的应用。
上述引物组合在制备诊断溃疡性结肠炎的产品中的应用。
一种溃疡性结肠炎检测试剂盒,包括上述的引物组合。
进一步地,上述检测试剂盒还包括mRNA逆转录试剂和mRNA qRT-PCR反应试剂。
有益效果:
1、采用qRT-PCR技术检测UC患者和健康对照者外周血CD4+T细胞中ETV5 mRNA表达水,为UC的临床诊治提供新的生物标志物和治疗靶点。
2、ETV5作为生物标志物用于UC诊断的敏感性高,特异性强,操作简单,结果稳定,具有广泛的临床应用前景。ETV5作为诊断标志物的特异度和灵敏度都达到90%以上,是诊断UC的比较可靠的特异性标志物。
附图说明
图1为实施例1中UC患者和健康对照者的ETV5表达差异分析;
图2为实施例1中ETV5表达水平对UC诊断的ROC曲线分析。
具体实施方式
下面结合具体实施例对本发明的技术方案作进一步说明。
实施例1
1.化合物:ETV5 qRT-PCR引物和GAPDH qRT-PCR引物。
ETV5上游引物 | ACGACACTTGTGTTGTGCCTGAG(SEQ ID No:2) |
ETV5下游引物 | GGCTGTTGTCATACTTCTCATGG(SEQ ID No:3) |
GAPDH上游引物 | GGAGCGAGATCCCTCCAAAAT(SEQ ID No:4) |
GAPDH下游引物 | CTTGAACTCCATGCCTCGACCTG(SEQ ID No:5) |
2.组合物:
(1)mRNA逆转录试剂:5×PrimerScript RT Master Mix,RNase-free H2O。(Takara生物公司提供)。
(2)mRNA qRT-PCR反应试剂:TB Green Premix Ex Taq(TaKaRa Ex Taq HS,dNTPMixture,Mg2+,Tli RNaseH,TB Green);ROX Reference Dye II;ETV5 qRT-PCR上游引物和下游引物。该方法以cDNA作为模板进行PCR反应时,可以很好地抑制由于cDNA中残存mRNA对PCR反应造成的阻害作用,对靶基因进行准确定量、检测,重复性好,可信度高。(Takara生物公司提供)。
3.方法:
(1)分离提取外周血CD4+T细胞:使用肝素抗凝试管收集UC患者和健康对照者外周静脉血10mL。将收集的外周血与等体积的磷酸缓冲盐溶液(phosphate buffer saline,PBS)混匀,缓慢加入淋巴细胞分离液上层,室温下2000rpm梯度离心20分钟。离心结束后用吸管缓慢吸取中间云雾层细胞置于50mL离心管中,用PBS清洗,1800rpm离心8分钟后弃上清可得到单个核细胞。将上述单个核细胞转移至流式管中,加入200微升CD4+T细胞分选磁珠(购自BD Biosciences),冰上孵育30分钟。孵育结束后将试管置于磁柱上提取CD4+T细胞,重复该步骤三次纯化CD4+T细胞并转移至无菌无酶EP管中,即为所需外周血CD4+T细胞样本。加入1mL Trizol室温放置5分钟后保存于-80℃冰箱中备用。
(2)RNA提取:将预先准备好的UC患者和健康对照者CD4+T细胞标本置于室温溶解,加入200微升氯仿,充分混匀并剧烈震荡15s后置于室温下5min。将上述标本在4℃、12000rpm条件下离心15min。离心结束后缓慢吸取上层清液400微升至另一EP管中,然后加入500微升异丙醇。缓慢混匀后室温静置10分钟,然后在4℃、12000rpm离心条件下离心10min可见RNA沉于EP管底部。弃去全部液体,加入75%乙醇静置5分钟在4℃,7500rpm条件下离心5min。离心结束后吸弃乙醇,置于室温下迅速烘干,可得到纯化后的RNA。加入适量DEPC水溶解RNA,使用Experion Automated Electrophoresis System(美国Bio-RadLaboratories)检测RNA纯度及浓度,A260/280介于1.8-2.0的RNA样本可用于后续PCR实验。
(3)mRNA逆转录:
使用Takara公司mRNA逆转录试剂盒对ETV5 mRNA进行逆转录获得模板cDNA,该试剂盒包含了:5×PrimerScript RT Master Mix,RNase-free H2O。
具体方法及步骤如下:将上述试剂取出后分别放置在冰上进行缓慢融解,待溶解完全后混匀,按照如下表格所示体积配制所需的反应溶液。
试剂组分 | 体积 |
RNA(400ng/μL) | 1μL |
5×PrimerScript RT Master Mix | 2μL |
RNase-free H<sub>2</sub>O | 7μL |
以上溶液混匀后,置于逆转录PCR仪中,使用逆转录反应程序为:37℃15分钟,85℃5秒。逆转录反应结束后,将所得cDNA样本迅速转移至冰上冷却,用于以下qRT-PCR实验。
(4)qRT-PCR实验
ETV5 qRT-PCR检测使用Takara公司mRNA检测剂盒,ETV5前引物、后引物,内参基因GAPDH前引物、后引物。qRT-PCR反应过程中ETV5和GAPDH cDNA扩增信号及CT值使用ABI公司的7500型实时PCR仪进行收集。
具体过程如下:将上述试剂取出后放置于冰上缓慢融解,待溶解完全后混匀,按照如下表格所示体积配制所需的反应溶液。
试剂组分 | 体积 |
cDNA模板 | 2μL |
TB Green Premix Ex Taq | 10μL |
ROX Reference Dye II | 0.4μL |
ETV5/GAPDH前引物 | 0.4μL |
ETV5/GAPDH后引物 | 0.4μL |
灭菌水 | 6.8μL |
按照上述溶液组分和体积配置反应液,加入96孔PCR板中,每个样本重复三次。反应条件为95℃30秒;95℃5秒,60℃34秒,40个循环。反应结束后,将每个样本的ETV5及内参基因GAPDH的CT值取平均值,拷贝后置于Excel表中进行分析。
计算公式如下:
ΔCT=ETV5基因CT值-内参基因GAPDH CT值;
ΔΔCT=UC患者ETV5基因ΔCT值-健康对照组ETV5基因ΔCT值;
相对值=2-ΔΔCT;
按照上述公式处理实验结果,分析ETV5在UC和健康对照者外周血CD4+T细胞中表达水平差异。
(5)统计学分析:
1)应用prism5统计软件,采用非配对样本t检验的方法分析ETV5在UC和健康对照者外周血CD4+T细胞中表达水平差异,以P<0.05为差异有统计学意义。
2)ETV5诊断价值评价应用prism5统计软件对数据进行受试者工作特征(receiveroperating characteristic,ROC)曲线分析,通过绘制ROC曲线并计算曲线下面积AUC评价ETV5诊断UC的敏感性和特异性。AUC<0.5时,表示诊断无意义;AUC=0.5-0.7时,表示诊断准确性较低;AUC=0.7-0.9时,表示诊断准确性中等;AUC>0.9时,表示诊断准确性高。
4.结果分析:
(1)如图1所示,UC患者外周血CD4+T细胞中ETV5表达比健康对照者ETV5表达水平显著上升,差异有统计学意义(p<0.05)。
(2)ETV5对UC的诊断价值:
利用ROC曲线分析ETV5在CD4+T细胞中的表达水平对UC诊断的检验效能,如图2所示:ETV5的ROC曲线下面积(area undercurve,AUC)为0.9297,灵敏度为82.76,特异度为84.62,提示ETV5作为UC诊断标志物的准确性、特异性及灵敏度均较高。
综上所述,UC患者CD4+T细胞中ETV5表达水平显著升高,ROC曲线分析结果显示AUC为0.9297,灵敏度为82.76,特异度为84.62。表明ETV5对UC有一定的诊断价值,是诊断UC的比较可靠的特异性生物标志物。
本发明利用RNA提取试剂提取健康对照者和UC患者外周血CD4+T细胞中总RNA分子,利用逆转录试剂制备ETV5模板cDNA。利用上述cDNA分子与ETV5 qRT-PCR引物、qRT-PCR试剂进行反应,检测ETV5在各样本中的CT值(CT值表示每个样本荧光强度达到阈值时所用的PCR循环数),利用相对值==2-ΔΔCT计算方法和非配对t检验方法比较ETV5在UC患者和健康对照者外周血CD4+T细胞表达差异。绘制ROC曲线并计算曲线下面积AUC,用于评价ETV5分子对UC诊断的特异性和敏感性。AUC<0.5时,表示无诊断意义;AUC=0.5-0.7时,表示诊断准确性较低;AUC=0.7-0.9时,表示诊断准确性中等;AUC>0.9时,表示诊断准确性较高。
通常由于UC胃肠道病变内镜下及组织病理学表现难以与其他消化道疾病相鉴别,使得UC的临床诊断面临许多难点。本发明利用qRT-PCR等方法检测ETV5在UC患者外周血CD4+T细胞中的表达水平,可作为生物标志物用于UC临床诊断,其特异度、灵敏度及准确性均较高。相对于现在所用的内镜检查及组织病理学检测方法,该检测方法更加快捷、方便,同时避免了肠镜检查存在的局限性,受试范围更加广泛。本发明中所用的qRT-PCR等方法操作简便,所用试剂及引物针对性强,可重复性强,结果稳定,有利于推广。
序列表
<110> 镇江市第一人民医院
<120> 一种用于溃疡性结肠炎诊断的mRNA标志物及其应用
<130> 20190620
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 4082
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
agagtccagc cgctggtgcg cggagcggtt caccgtcttc ggagcggttc ggcccagcct 60
ttcgcccagg cgcccaggcc cgctgcgcgc gtgcgtgagc gcgcctgcgc cgccggggcc 120
gctgcaaggg gaggagagag gccgcctcag gaggatccct tttcccccag aaattactca 180
atgctgaaac ctctcaaagt ggtattagag acgctgaaag caccatggac gggttttatg 240
atcagcaagt cccttttatg gtcccaggga aatctcgatc tgaggaatgc agagggcggc 300
ctgtgattga cagaaagagg aagtttttgg acacagatct ggctcacgat tctgaagagc 360
tatttcagga tctcagtcaa cttcaagagg cttggttagc tgaagcacaa gttcctgatg 420
atgaacagtt tgtcccagat tttcagtctg ataacctggt gcttcatgcc ccacctccaa 480
ccaagatcaa acgggagctg cacagcccct cctctgagct gtcgtcttgt agccatgagc 540
aggctcttgg tgctaactat ggagaaaagt gcctctacaa ctattgtgcc tatgatagga 600
agcctccctc tgggttcaag ccattaaccc ctcctacaac ccccctctca cccacccatc 660
agaatcccct atttccccca cctcaggcaa ctctgcccac ctcagggcat gcccctgcag 720
ctggcccagt tcaaggtgtg ggccccgccc ccgcccccca ttcgcttcca gagcctggac 780
cacagcagca aacatttgcg gtcccccgac caccacatca gcccctgcag atgccaaaga 840
tgatgcctga aaaccagtat ccatcagaac agagatttca gagacaactg tctgaaccct 900
gccacccctt ccctcctcag ccaggagttc ctggagataa tcgccccagt taccatcggc 960
aaatgtcaga acctattgtc cctgcagctc ccccgccccc tcagggattc aaacaagaat 1020
accatgaccc actctatgaa catggggtcc cgggcatgcc agggccccca gcacacgggt 1080
tccagtcacc aatgggaatc aagcaggagc ctcgggatta ctgcgtcgat tcagaagtgc 1140
ctaactgcca gtcatcctac atgagagggg gttatttctc cagcagccat gaaggttttt 1200
catatgaaaa agatccccga ttatactttg acgacacttg tgttgtgcct gagagactgg 1260
aaggcaaagt caaacaggag cctaccatgt atcgagaggg gcccccttac cagaggcgag 1320
gttcccttca gctgtggcag ttcctggtca cccttcttga tgacccagcc aatgcccact 1380
tcattgcctg gacaggtcga ggcatggagt tcaagctgat agaaccggaa gaggttgctc 1440
ggcgctgggg catccagaag aaccggccag ccatgaacta tgacaagctg agccgctctc 1500
tccgctatta ctatgaaaag ggcatcatgc agaaggtggc tggagagcga tacgtctaca 1560
aatttgtctg tgacccagat gccctcttct ccatggcttt cccggataac cagcgtccgt 1620
tcctgaaggc agagtccgag tgccacctca gcgaggagga caccctgccg ctgacccact 1680
ttgaagacag ccccgcttac ctcctggaca tggaccgctg cagcagcctc ccctatgccg 1740
aaggctttgc ttactaagtt tctgagtggc ggagtggcca aaccctagag ctagcagttc 1800
ccattcaggc aaacaagggc agtggttttg tttgtgtttt tggttgttcc taaagcttgc 1860
cctttgagta ttatctggag aacccaagct gtctctggat tggcaccctt aaagacagat 1920
acattggctg gggagtggga acagggaggg gcagaaaacc accaaaaggc cagtgcctca 1980
actcttgatt ctgatgaggt ttctgggaag agatcaaaat ggagtctcct taccatggac 2040
aatacatgca aagcaatatc ttgttcaggt tagtacccgc aaaacgggac atagtatgtg 2100
acaatctgca tcgatcatgg actactaaat gcctttacat agaagggctc tgatttgcac 2160
aatttgttga aaaatcacaa acccatagaa aagtaagtag gctaagttgg ggaggctcaa 2220
accattaagg gttaaaaata catcttaaac attggaaagc tcttctagct gaatctgaaa 2280
tattacccct tgtctagaaa aaggggggca gtcagaacag ctgttcccca ctccgtggtt 2340
ctcaaaatca taaaccatgg ctactcttgg gaaccacccg gccatgtggt cgccaagtag 2400
agcaagcccc ctttctcttc ccaatcacgt ggctgagtgt ggatgacttt tattttagga 2460
gaagggcgat taacactttt gacagtattt tgttttgccc tgatttgggg gattgttttg 2520
ttttggtggt tgttttggaa aaacagttta taaactgatt tttgtagttt tggtatttaa 2580
agcaaaaaaa cgaaaaacaa aaaacaaaaa caaacctttt ggtaactgtg cactgtgtcc 2640
tttagccagg gccgtgccaa cttatgaaga cactgcagct tgagaggggc tttgctgagg 2700
cttccccttg gccatgtgaa agcccgcctt gttgcctgct ttgtgctttc tgcaccagac 2760
aacctgatgg aacatttgca cctgagttgt acatttttga agtgtgcagg gcagcctgga 2820
cacaagctta gattctctat gtatagttcc ccgtgttcac taacatgccc tctctggaaa 2880
gcatatgtat ataacatgtg tcatgtcctt tggaaacctg gtcacctggt gaaaaccctt 2940
gggattcttc cctgggcatg actgatgaca atttccattt catcagtttg ttttgttttc 3000
ctttttcttt aaatcttgga ctttaaaccc tacctgtgtg attcagtagg gtttgagact 3060
tacgtgtgat actgacaggt aagcaacagt gctagcattc tagattcctg ccttttttta 3120
aaaagaaatt attctcattg ctgtattata ttggaaaagt tttaaacaac caagctaaag 3180
ctatgtgaaa gttgagctca aagtagagga aaagttactg gtggtacctt gctgcctgct 3240
ctgctggtag aattctgtgc tccccgtgac acttagtaca ttaagaatga ctacactgtt 3300
cctcgtatgt gaaggaggca gtgctgactc cgtgagtgtg agacacgtgc tttgaactgc 3360
ttttctattc atggagcact ccatagtctc aaactgtccc ccttatgacc aacagcacat 3420
ttgtgaagag gttcgcaggg ataaggggtg cactttatag ctatggaaac atgagattct 3480
cctctattgg aagctaatta gcccacaaag gtggtaaacc tgtagattgg gccttaatta 3540
gcattgtact ctaatcaaag gactctttct aaaccatatt tatagctttc ttaacctaca 3600
catagtctat acatagatgc atattttacc cccagctggc tagagattta tttgttgtaa 3660
atgctgtata gatttggttt tcctttcttt acttaccctg gtttggattt tttttttttt 3720
tcttttgaat ggatttatgc tgtcttagca atatgacaat aatcctctgt agcttgagct 3780
acccctcccc tgctgtaact tacgtgacct gtgctgtcac tgggcatagg acagcggcat 3840
cacggttgca ttcccattgg actcatgcac ctcccggatg gtttttgttt ttttcggggg 3900
ttctttgggg tttgtttgtt tgcttctttt ccagagtgtg gaaagtctac agtgcagaaa 3960
ggcttgaacc tgccagctga tttgaaatac tttcccctgc gcagggccgt atgcatcctg 4020
ccaagctgcg ttatattctg tactgtgtac aataaagaag tttgcttttc gtttaccaag 4080
ca 4082
<210> 2
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
acgacacttg tgttgtgcct gag 23
<210> 3
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
ggctgttgtc atacttctca tgg 23
<210> 4
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 4
ggagcgagat ccctccaaaa t 21
<210> 5
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 5
cttgaactcc atgcctcgac ctg 23
Claims (1)
1.用于检测mRNA标志物的引物对在制备检测溃疡性结肠炎诊断试剂盒中的应用,该标志物为SEQ ID No:1 所示的ETV5;所述引物对包括如SEQ ID No:2所示的上游引物和如SEQID No:3所示的下游引物,所述试剂盒包括mRNA逆转录试剂和mRNA qRT-PCR反应试剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910536229.XA CN110373457B (zh) | 2019-06-20 | 2019-06-20 | 一种用于溃疡性结肠炎诊断的mRNA标志物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910536229.XA CN110373457B (zh) | 2019-06-20 | 2019-06-20 | 一种用于溃疡性结肠炎诊断的mRNA标志物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110373457A CN110373457A (zh) | 2019-10-25 |
CN110373457B true CN110373457B (zh) | 2023-03-14 |
Family
ID=68249032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910536229.XA Active CN110373457B (zh) | 2019-06-20 | 2019-06-20 | 一种用于溃疡性结肠炎诊断的mRNA标志物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110373457B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112941150A (zh) * | 2021-03-25 | 2021-06-11 | 安徽医科大学 | 一种筛选溃疡性结肠炎疾病活动度指标的方法 |
CN114107484B (zh) * | 2021-12-08 | 2024-03-22 | 上海锐翌生物科技有限公司 | 溃疡性结肠炎标志基因及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008147938A2 (en) * | 2007-05-24 | 2008-12-04 | Centocor, Inc. | Wnt5a as an inflammatory disease marker |
CA2966772A1 (en) * | 2014-11-10 | 2016-05-19 | The Regents Of The University Of California | Mir-214 as a diagnostic and prognostic biomarker specific for ulcerative colitis and a mir-214 inhibitor for treatment of same |
JP2018085989A (ja) * | 2012-10-05 | 2018-06-07 | ジェネンテック, インコーポレイテッド | 炎症性腸疾患の診断治療方法 |
CN108165624A (zh) * | 2018-03-09 | 2018-06-15 | 蚌埠医学院第附属医院(蚌埠医学院附属肿瘤医院) | 生物标志物在骨肉瘤诊治中的应用 |
CN108796066A (zh) * | 2018-06-28 | 2018-11-13 | 镇江市第人民医院 | 与克罗恩病相关的miRNA标志物及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013059732A1 (en) * | 2011-10-21 | 2013-04-25 | Nestec S.A. | Methods for improving inflammatory bowel disease diagnosis |
-
2019
- 2019-06-20 CN CN201910536229.XA patent/CN110373457B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008147938A2 (en) * | 2007-05-24 | 2008-12-04 | Centocor, Inc. | Wnt5a as an inflammatory disease marker |
JP2018085989A (ja) * | 2012-10-05 | 2018-06-07 | ジェネンテック, インコーポレイテッド | 炎症性腸疾患の診断治療方法 |
CA2966772A1 (en) * | 2014-11-10 | 2016-05-19 | The Regents Of The University Of California | Mir-214 as a diagnostic and prognostic biomarker specific for ulcerative colitis and a mir-214 inhibitor for treatment of same |
CN108165624A (zh) * | 2018-03-09 | 2018-06-15 | 蚌埠医学院第附属医院(蚌埠医学院附属肿瘤医院) | 生物标志物在骨肉瘤诊治中的应用 |
CN108796066A (zh) * | 2018-06-28 | 2018-11-13 | 镇江市第人民医院 | 与克罗恩病相关的miRNA标志物及其应用 |
Non-Patent Citations (2)
Title |
---|
miR-155 下调 Ets-1 参与溃疡性结肠炎的发病机制;陈斌等;《中药新药与临床药理》;20150531;第26卷(第3期);第307-310页 * |
NCBI Reference Sequence: NM_004454.3;Pan Y等;《NCBI》;20181224;第1-4页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110373457A (zh) | 2019-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9920375B2 (en) | Biomarkers in peripheral blood mononuclear cells for diagnosing or detecting lung cancers | |
CN104450901B (zh) | 快速诊断川崎病的核酸标记物及其试剂盒 | |
WO2010105275A2 (en) | Method to assess human allograft status from microrna expression levels | |
CN102876676A (zh) | 一种与胰腺癌相关的血清/血浆miRNA标志物及其应用 | |
CN108588226A (zh) | 检测乳腺癌脑转移的miRNA组合及含有该组合的试剂盒 | |
CN110373457B (zh) | 一种用于溃疡性结肠炎诊断的mRNA标志物及其应用 | |
CN109055538B (zh) | 一种类风湿性关节炎的外泌体miRNA标志物及试剂盒 | |
CN110305953B (zh) | 检测miRNA表达量的系统在制备区分结核性脑膜炎和病毒性脑膜炎产品中的应用 | |
CN115976189A (zh) | 一种用于脑梗诊断与检测的生物标志物及其相关应用 | |
CN108866187B (zh) | 一种与肺癌辅助诊断相关的长链非编码rna标志物及其应用 | |
CN110791562A (zh) | 用于检测2型糖尿病的miR-145-5P分子标记物及其扩增引物和应用 | |
EP4534698A1 (en) | Liver-cancer-related serum microrna marker and new method for diagnosing liver cancer | |
CN108796066A (zh) | 与克罗恩病相关的miRNA标志物及其应用 | |
WO2012019786A1 (en) | Method and kit for the diagnosis and/or prognosis of tolerance in liver transplantation | |
CN107904303A (zh) | 用于检测胆道闭锁患儿血浆miR‑140‑3p的引物组及包含该引物组的检测试剂盒 | |
WO2017129977A1 (en) | Chronic kidney disease diagnostic | |
CN110295232A (zh) | 用于结直肠癌的microRNA生物标记物 | |
CN115772558A (zh) | 一种用于肝衰竭疾病转归预后评价的试剂盒及应用及应用方法 | |
CN111718988B (zh) | 一种血浆长链非编码rna在冠心病筛查中的应用 | |
CN108034702A (zh) | 检测融合基因mll/cbp的表达情况及融合型别的寡核苷酸及应用 | |
CN113980968A (zh) | 一种新的ra标志长链非编码rna及其应用 | |
CN118813803B (zh) | 一种诊断骨髓增生异常综合征的miRNA标志物、试剂盒及应用 | |
CN110699450A (zh) | miRNA生物标志物在肝脏疾病诊断和预后判断中的应用 | |
CN118006761B (zh) | 外泌体miRNA作为诊断扩心病合并心衰的分子标志物及其应用 | |
CN108531570B (zh) | 原发性胆汁性肝硬化的诊断试剂盒及相关基因在制备该试剂盒中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |